SG11202002174SA - Human cytomegalovirus immunogenic composition - Google Patents

Human cytomegalovirus immunogenic composition

Info

Publication number
SG11202002174SA
SG11202002174SA SG11202002174SA SG11202002174SA SG11202002174SA SG 11202002174S A SG11202002174S A SG 11202002174SA SG 11202002174S A SG11202002174S A SG 11202002174SA SG 11202002174S A SG11202002174S A SG 11202002174SA SG 11202002174S A SG11202002174S A SG 11202002174SA
Authority
SG
Singapore
Prior art keywords
immunogenic composition
human cytomegalovirus
cytomegalovirus immunogenic
human
composition
Prior art date
Application number
SG11202002174SA
Other languages
English (en)
Inventor
Pascal Chaux
Rafaela Dumas
Jean Haensler
Sylvie Pichon
Fabienne Piras-Douce
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of SG11202002174SA publication Critical patent/SG11202002174SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202002174SA 2017-09-13 2018-09-11 Human cytomegalovirus immunogenic composition SG11202002174SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306179 2017-09-13
PCT/EP2018/074369 WO2019052975A1 (fr) 2017-09-13 2018-09-11 Composition immunogène contre le cytomégalovirus humain

Publications (1)

Publication Number Publication Date
SG11202002174SA true SG11202002174SA (en) 2020-04-29

Family

ID=60782111

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002174SA SG11202002174SA (en) 2017-09-13 2018-09-11 Human cytomegalovirus immunogenic composition

Country Status (13)

Country Link
US (3) US11524069B2 (fr)
EP (1) EP3681534A1 (fr)
JP (2) JP2020533354A (fr)
KR (1) KR20200051778A (fr)
CN (1) CN111344009A (fr)
AU (1) AU2018331874B2 (fr)
BR (1) BR112020004747A2 (fr)
CA (1) CA3075207A1 (fr)
IL (1) IL273120B2 (fr)
MX (1) MX2020002810A (fr)
SG (1) SG11202002174SA (fr)
WO (1) WO2019052975A1 (fr)
ZA (1) ZA202001561B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL273120B2 (en) 2017-09-13 2023-10-01 Sanofi Pasteur A compound that induces an immune response to cytomegalovirus
US20220023416A1 (en) * 2018-12-10 2022-01-27 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
MX2023005018A (es) 2020-10-28 2023-05-16 Sanofi Pasteur Liposomas que contienen un agonista de tlr4, preparacion y usos de los mismos.

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US6100064A (en) * 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (fr) 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0463056A1 (fr) 1989-03-17 1992-01-02 E.I. Du Pont De Nemours And Company Regulation externe de l'expression de genes
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US20020102562A1 (en) 1995-05-24 2002-08-01 Pasteur Merieux Serums Et Vaccines S.A. Recombinant CMV neutralizing proteins
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
CA2511512C (fr) 2002-12-27 2013-10-29 Chiron Corporation Immunogenes contenant des compositions de phospholipide
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US20090104227A1 (en) * 2007-09-21 2009-04-23 Sanofi Pasteur Vaccine composition for the prevention of cmv infection
KR101695800B1 (ko) 2008-03-05 2017-02-22 사노피 파스퇴르 항원보강제 함유 백신 조성물의 안정화 방법
CA2764374C (fr) 2009-06-05 2019-11-19 Infectious Disease Research Institute Adjuvants lipidiques synthetiques a base de glucopyranosyle
KR102266691B1 (ko) * 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
JP6138047B2 (ja) 2010-10-15 2017-05-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サイトメガロウイルスｇＢ抗原
CN103596586A (zh) * 2011-04-08 2014-02-19 免疫设计公司 免疫原性组合物及使用所述组合物诱导体液和细胞免疫反应的方法
US9683022B2 (en) * 2012-07-06 2017-06-20 Glaxosmithkline Biologicals S.A. Complexes of cytomegalovirus proteins
AU2013293570B2 (en) * 2012-07-27 2019-05-23 City Of Hope An MVA vaccine for delivery of a UL128 complex and preventing CMV infection
SG11201501623PA (en) * 2012-10-30 2015-05-28 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
TW201609792A (zh) 2014-05-08 2016-03-16 輝瑞大藥廠 治療ｃｍｖ之手段及方法
EP3031822A1 (fr) 2014-12-08 2016-06-15 Novartis AG Antigènes du cytomégalovirus
WO2017044895A2 (fr) * 2015-09-10 2017-03-16 City Of Hope Anticorps générés par le vaccin mva-gh/gl-pc neutralisant le pouvoir infectieux du cytomégalovirus humain et procédés associés
JP6921833B2 (ja) * 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
US11554170B2 (en) * 2016-06-17 2023-01-17 Sanofi Pasteur Sa Immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
IL273120B2 (en) 2017-09-13 2023-10-01 Sanofi Pasteur A compound that induces an immune response to cytomegalovirus

Also Published As

Publication number Publication date
US20230277655A1 (en) 2023-09-07
AU2018331874B2 (en) 2022-06-02
US11524069B2 (en) 2022-12-13
MX2020002810A (es) 2020-07-21
JP2020533354A (ja) 2020-11-19
CN111344009A (zh) 2020-06-26
JP2024026160A (ja) 2024-02-28
AU2018331874A1 (en) 2020-04-30
ZA202001561B (en) 2021-07-28
IL273120B2 (en) 2023-10-01
RU2020113253A3 (fr) 2021-11-17
WO2019052975A1 (fr) 2019-03-21
KR20200051778A (ko) 2020-05-13
US20210023202A1 (en) 2021-01-28
IL273120B1 (en) 2023-06-01
RU2020113253A (ru) 2021-10-18
IL273120A (en) 2020-04-30
EP3681534A1 (fr) 2020-07-22
US20200276301A1 (en) 2020-09-03
BR112020004747A2 (pt) 2020-09-24
CA3075207A1 (fr) 2019-03-21
US11207403B2 (en) 2021-12-28
WO2019052975A9 (fr) 2020-04-09

Similar Documents

Publication Publication Date Title
IL273541A (en) formulations
IL268697A (en) Formulations
EP3528821A4 (fr) Vaccin contre le cytomégalovirus humain
EP3364981A4 (fr) Vaccin contre le cytomégalovirus humain
IL269630A (en) Niraprib formulations
IL269621A (en) Niraparib formulations
IL273282A (en) Niraprib formulations
GB201610599D0 (en) Immunogenic Composition
ZA202001561B (en) Human cytomegalovirus immunogenic composition
GB201711635D0 (en) Immunogenic composition
EP3294409C0 (fr) Prothèse visuelle corticale
GB201802339D0 (en) Immunogenic composition
GB201707189D0 (en) Novel formulations
GB201711637D0 (en) Immunogenic composition
GB201707188D0 (en) Novel formulations
GB2562241B (en) Vaccine compositions
GB201614485D0 (en) Immunogenic composition
IL282753A (en) Immunogenic compounds
IL271603A (en) Immunogenic preparations
GB201604755D0 (en) Immunogenic compositions
GB201703529D0 (en) Vaccine composition
GB201707187D0 (en) Novel formulations
GB201803692D0 (en) Immunogenic composition
GB201718251D0 (en) Vaccine Compositions
GB201911959D0 (en) Immunogenic compositions and uses therefor